Brought to you by 
Biogen Idec gets option to Isis' antisense compound for spinal muscular atrophy
30 Aug 2017
Executive Summary
In a deal potentially worth $299mm, Isis Pharmaceuticals Inc. has licensed fellow public biotech Biogen Idec Inc. an exclusive worldwide option to develop and commercialize its antisense compound ISIS-SMNRx, which is in Phase I for spinal muscular atrophy (SMA).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen Idec gets option to Isis' antisense compound for spinal muscular atrophy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice